van Deen, Welmoed K. http://orcid.org/0000-0002-4836-9849
Kiaei, Ben
Weaver, S. Alandra
Crate, Damara J.
Kwon, Michelle H.
Shah, Samir A.
Melmed, Gil Y.
Siegel, Corey A.
Funding for this research was provided by:
Crohn's and Colitis Foundation
Article History
Accepted: 25 March 2020
First Online: 11 April 2020
Compliance with ethical standards
:
: WKvD: Grant Funding from Crohn's and Colitis Foundation; SAW: Employee of the Crohn’s and Colitis Foundation; GYM: Consultant: Abbvie, Boehringer-Ingelheim, Celgene, Janssen, Pfizer, Samsung Bioepis, Takeda; CAS: Consultant/Advisory Board: Abbvie, Amgen, BMS, Celgene, Lilly, Janssen, Sandoz, Pfizer, Prometheus, Sebela, Takeda; Speaker for CME activities: Abbvie, Celgene, Janssen, Pfizer, Takeda; Grant support: Crohn’s and Colitis Foundation, AHRQ (1R01HS021747-01), Broad Medical Research Program, Abbvie, Janssen, Pfizer, Takeda; Intellectual property: MiTest Health, LLC has a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors; Equity Interest: Dr. Corey Siegel and Dr. Lori Siegel are co-founders of MiTest Health, LLC. BK, DJC, MHK and SAS do not have any financial disclosures or conflict of interest to report.
: Institutional Review Board (IRB) approval was obtained for all participating sites: Gastroenterology Associates relied on the University of Southern California IRB under protocol number HS-18-00424. The Cedars-Sinai Medical Center IRB approved this under protocol number Pro00054443 and the Dartmouth-Hitchcock Medical Center approved it under protocol number STUDY00031555. All procedures performed in studies involving human participants were in accordance with the ethical standards of these IRBs and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All participants were provided with an information sheet and verbally consented to participate in this study.